No abstract

Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of ∼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer’s Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company’s ‘lightspeed’ paradigm.

No abstract

This paper describes the results of an effort to predict future freight volume in the truckload (TL) trucking industry. The approach involves the use of stepwise multiple linear regression models that relate freight volume to a variety of economic indicators. The models are built using a large set of actual freight data provided by J.B. Hunt Transport (JBHT), one of the world’s largest TL carriers. The data was first analyzed using the overall set of national data, and then for specific industrial and regional segments. The overall results of these analyses should prove useful to a wide variety of transportation and logistics operations.

No abstract